Biohaven's BHV-1530 cancer drug shows promise; Phase 1 data to be presented at ENA 2026 symposium.

Biohaven announced that Phase 1 data for BHV-1530, a novel FGFR3-targeting antibody-drug conjugate for advanced cancers, will be presented at the ENA 2026 symposium. BHV-1530 has demonstrated early clinical activity with a favorable safety profile, avoiding common toxicities seen in similar drugs. The company has also started enrolling patients in a trial combining BHV-1530 with Regeneron's cemiplimab, aiming to enhance treatment efficacy. This progress highlights BHV-1530's potential as a new therapy for FGFR3-driven tumors, including those not addressed by current FGFR inhibitors.

Regeneron Pharmaceuticals Inc (REGN) is trading at USD 781.16 on Pluang as of Sep 28, 2026 18:42 WIB, down 0.87% for the day. The article's mention of Biohaven's trial combining BHV-1530 with Regeneron's cemiplimab ties directly to REGN's current market activity. REGN holds a market cap of $81.13 billion and a dividend yield of 0.48%, reflecting its significant presence in the health sector.